NEW YORK (GenomeWeb) – Trovagene reported after the close of the market on Thursday that its second quarter revenues more than doubled year over year, though it missed analysts' consensus estimate on the top and bottom lines.

For the three months ended June 30, the San Diego-based molecular diagnostic developer posted revenues of $104,000 compared to $50,000 in Q2 2015, missing the Wall St. estimate of $270,000 in revenues.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.